

## ABSTRACT

Curr Opin Oncol. 2021 Sep 3. doi: 10.1097/CCO.0000000000000788. Online ahead of print.

### **Current treatments of medulloblastoma.**

Beccaria K(1), Padovani L, Bouchoucha Y, Doz F.

#### Author information:

(1)Department of Pediatric Neurosurgery, Hôpital Necker-Enfants Malades  
Université de Paris, Paris Department of Radiation Oncology, Assistance Publique  
Hôpitaux de Marseille, Marseille SIREDO Center (Care, Innovation, Research in,  
Children, Adolescent and Young Adults Oncology), Institut Curie, Paris, France.

**PURPOSE OF REVIEW:** The biological knowledge and the new biopathological classification of medulloblastoma subtypes have dramatically changed the therapeutic indications, taking into account not only age and staging but also biopathological risk criteria. This review covers the multidisciplinary approach including surgery, radiation oncology and medical treatments.

**RECENT FINDINGS:** The neurosurgical management of tumor-related hydrocephalus has been modified by the introduction of third ventriculostomy. The initial complete excision is no longer always the first choice, to preserve neurological function. The recent technical improvements of radiotherapy are also implemented to optimize outcome in terms of survival as well as quality of survival. The different medical treatments are adapted according to age and risk factors. The role of high-dose chemotherapy with autologous hematopoietic stem cell rescue has become larger in the high-risk situations.

**SUMMARY:** The rarity of the disease and the high-level of technicity of diagnosis, biopathological subtyping and treatments justifies the referral of these patients to highly specialized centers where all these techniques can be routinely applied, most often in the context of international prospective studies.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

DOI: 10.1097/CCO.0000000000000788  
PMID: 34482338